BIOLIFE SOLUTIONS INC
biolifesolutions.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2026 10-Q, filed Aug 6, 2026. Its latest SEC filing is a 15-12G from Oct 16, 2026.
10-Q for Q2 FY2026, filed Aug 6, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells biopreservation media, cell-processing tools and thawing devices to cell and gene therapy customers, researchers, and manufacturers of biologic therapies.
10-K for FY2025, filed Feb 26, 2026We are a life sciences company that develops, manufactures, and markets bioproduction products and services which are designed to improve…View ↗
Our bioproduction products and services are comprised of one revenue line that contains three main offerings:View ↗
Our proprietary biopreservation media products, HypoThermosol® FRS and CryoStor® Freeze Media, are formulated to mitigate…View ↗
Our bioproduction products portfolio includes human platelet lysates for cell expansion, which reduces risk and improves downstream…View ↗
The ThawSTAR® line includes thawing products that control the temperature and timing of the thawing process of biologic material. Our…View ↗
How Did They Make Money?
Customers mainly buy biopreservation media and cell-processing tools; BioLife is generally paid when products ship, with payment terms generally requiring payment within 30 to 60 days.
10-K for FY2025, filed Feb 26, 2026
$96.2M
-
10-K for FY2025, filed Feb 26, 2026
$96.2M ↗
Who Were Their Customers?
BioLife uses field-based sales employees for direct sales and regional distributors under non-exclusive agreements to market and distribute its products.
10-K for FY2025, filed Feb 26, 2026
Did Revenues Turn Into Profits?
Not on paper. It lost $4.6M in FY2025, but brought in more cash than it spent: $10.6M of free cash flow.
10-K for FY2025, filed Feb 26, 2026
−$16.6MView ↗
10-K for FY2025, filed Feb 26, 2026
−$4.6MView ↗
10-K for FY2025, filed Feb 26, 2026
$10.6MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
$45.1MView ↗
- ▲ Now profitable
- vs −$15.8M in Q2 FY2025
-
Sep 3, 2026
Antitrust waiting period expired for Repligen merger
The merger still requires stockholder approval and satisfaction of other customary closing conditions.
Sources
8-K, filed Sep 9, 2026
As previously disclosed, on July 21, 2026, BioLife Solutions, Inc., a Delaware corporation (“BioLife”), entered into an Agreement and Plan…View ↗
-
Jul 22, 2026
Repligen agreed to acquire BioLife
The agreement would make BioLife a wholly owned subsidiary of Repligen after the merger.
Sources
8-K, filed Jul 22, 2026
On July 21, 2026, BioLife Solutions, Inc., a Delaware corporation (“BioLife” or the “Company”), entered into an Agreement and Plan of…View ↗
Shrank. Revenue fell 19% in 4 years, from $119.2M in FY2021 to $96.2M in FY2025, about 5% a year.
Narrower product portfolio
The older report describes biopreservation, cell processing, frozen storage and cold-chain transport; the latest focuses on biopreservation media and cell processing after sales of freezer, storage and shipping businesses.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Feb 26, 2026We currently operate as one bioproduction tools and services business which supports several steps in the biologic material manufacturing…View ↗
We currently operate as one bioproduction products and services business which supports several steps in the biologic material…View ↗
On October 6, 2025, the Company entered into a Limited Liability Company Membership Interest Purchase Agreement (the “SAVSU Purchase…View ↗
On November 14, 2024, the Company entered into a Stock Purchase Agreement (the “CBS Purchase Agreement”), by and among the Company, Standex…View ↗
On November 12, 2024, the Company entered into a Stock Purchase Agreement (the “SciSafe Purchase Agreement”), by and among the Company…View ↗
On April 17, 2024, the Company sold all of the issued and outstanding shares of common stock of Global Cooling, Inc., a Delaware…View ↗
Loading...
